HORMONE SENSITIVE PROSTATE CANCER
Clinical trials for HORMONE SENSITIVE PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE SENSITIVE PROSTATE CANCER trials appear
Sign up with your email to follow new studies for HORMONE SENSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Triple-Threat attack on spreading prostate cancer
Disease control OngoingThis study is testing a combination of three types of drugs—hormone therapy, chemotherapy, and immunotherapy—to see if they work better together to control advanced prostate cancer that has just started to spread. It is for men newly diagnosed with a high amount of cancer spread.…
Matched conditions: HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: Xiao X. Wei, MD • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New 'Tumor-Seeking' radiation therapy enters human trials for prostate cancer
Disease control OngoingThis clinical trial is testing a new targeted radiation treatment called [Ac-225]-PSMA-62 for men with advanced prostate cancer that has spread. The treatment uses a radioactive drug designed to find and deliver radiation directly to prostate cancer cells throughout the body. The…
Matched conditions: HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New hope to delay cancer progression in advanced prostate cancer
Disease control OngoingThis large, late-stage study is testing whether adding an experimental drug called capivasertib to standard hormone therapy (abiraterone) works better for men whose prostate cancer has already spread and has a specific genetic feature (PTEN deficiency). The main goal is to see if…
Matched conditions: HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Can men 'Comeback' from prostate cancer treatment? trial tests hormone recovery
Disease control OngoingThis study is testing a two-drug combination (relugolix and darolutamide) for men with hormone-sensitive prostate cancer. The main goal is to see if men's testosterone levels return to normal within 18 months after finishing the two-year treatment. Researchers will also closely m…
Matched conditions: HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: Atish Choudhury, MD • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC
-
Prostate cancer drugs put to the test: which one protects your mind?
Symptom relief OngoingThis study aims to find out which of two common prostate cancer medications—enzalutamide or darolutamide—has less impact on memory, concentration, and other thinking skills. About 111 men with advanced prostate cancer will take one of the drugs and complete regular computer-based…
Matched conditions: HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Symptom relief
Last updated Mar 23, 2026 15:19 UTC
-
Doctors test High-Tech scans to monitor prostate cancer
Knowledge-focused OngoingThis study aims to learn if a special type of scan called a PSMA-PET can be used to monitor how well treatment is working for men with metastatic prostate cancer that still responds to hormone therapy. Twenty participants will receive standard treatment and undergo two of these s…
Matched conditions: HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:43 UTC